|
Signature Peptide
|
Study I
|
Study II
|
Study IIIa
|
|---|
| |
Inter- site CV
|
Intra- site CV
|
Linear Slope
|
% Recov.
|
Inter- site CV
|
Intra- site CV
|
Linear Slope
|
% Recov.
|
Inter- site CV
|
Intra- site CV
|
Linear Slope
|
% Recov.
|
|---|
|
APR-AGL
|
9.20%
|
3.9-11.2%
|
1.157
|
114.5
|
13.10%
|
2.0-7.8%
|
0.575
|
57.5
|
13.70%
|
7.3-45.2%
|
0.738
|
79.4
|
|
CRP-ESD
|
5.90%
|
2.2-5.9%
|
1.124
|
118.4
|
10.50%
|
3.1-8.4%
|
0.573
|
61.4
|
16.70%
|
8.5-18.1%
|
0.439
|
48.9
|
|
CRP-GYS
|
5.40%
|
1.4-10.2%
|
1.324
|
140.5
|
5.60%
|
1.2-6.4%
|
0.546
|
56
|
18.50%
|
6.6-35.0%
|
0.159
|
18.5
|
|
HRP-SSD
|
14.10%
|
4.0-8.9%
|
1.198
|
120.4
|
5.50%
|
4.6-7.3%
|
0.794
|
82.3
|
21.90%
|
8.4-21.4%
|
0.43
|
45.7
|
|
LEP-IND
|
12.50%
|
2.9-10.3%
|
1.163
|
119.1
|
29.50%
|
2.6-15.3%
|
0.152
|
14.9
|
50.40%
|
11.7-54.9%
|
0.242
|
25.6
|
|
MBP-HGF
|
4.30%
|
1.7-6.3%
|
1.161
|
118.6
|
9.30%
|
1.5-7.8%
|
0.758
|
77.3
|
21.80%
|
7.4-32.8%
|
0.238
|
23.8
|
|
MBP-YLA
|
5.10%
|
2.1-9.3%
|
1.275
|
130.3
|
4.10%
|
1.5-14.1%
|
0.806
|
83.8
|
N/A
|
N/A%
|
N/A
|
> 1.0
|
|
MYO-LFT
|
4.90%
|
1.6-5.7%
|
1.518
|
154.4
|
3.80%
|
2.0-6.3%
|
1.012
|
101.3
|
23.10%
|
8.9-21.6%
|
0.504
|
60.4
|
|
PSA-IVG
|
6.90%
|
1.3-14.7%
|
1.658
|
165.4
|
5.50%
|
2.0-11.2%
|
0.848
|
81.9
|
17.20%
|
7.6-13.7%
|
0.587
|
58
|
|
PSA-LSE
|
8.90%
|
1.2-6.9%
|
1.098
|
111.4
|
5.30%
|
2.0-4.6%
|
1.524
|
151.3
|
10.30%
|
7.6-13.7%
|
0.918
|
92.7
|
- The CVs increase in distribution between studies I, II, and III as expected with increasing complexity of the three studies. Adapted from Addona, et. al., Nature Biotechnology, 27(7):633-41 (25).
